Literature DB >> 17306453

High throughput proteomic strategies for identifying tumour-associated antigens.

C Geeth Gunawardana1, Eleftherios P Diamandis.   

Abstract

Tumours elicit an immune response in the host organism and this area has been studied for decades. Initially, tumour-associated antigens were studied by examining a few proteins at a time using techniques such as 1-D SDS-PAGE and sandwich ELISAs. Now, however, with the development of high-throughput strategies, multiple potential antigens in a single experiment could be uncovered. The prevailing view is that these antigens can be used as biosensors for cancers. In addition, some of these antigens may indeed be used as targets for immunotherapy. SEREX, SERPA, and protein microarray technology have been the three dominant strategies employed to identify tumour-associated antigens. In this mini-review, we aim to describe these three techniques and provide their advantages and disadvantages. In addition, we aim to address some of the challenges of cancer immunomics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17306453     DOI: 10.1016/j.canlet.2007.01.002

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  26 in total

1.  Microarray methods for protein biomarker detection.

Authors:  Hye Jin Lee; Alastair W Wark; Robert M Corn
Journal:  Analyst       Date:  2008-06-05       Impact factor: 4.616

2.  Proteome-based analysis of serologically defined tumor-associated antigens in cutaneous lymphoma.

Authors:  Michael Forgber; Sylke Gellrich; Tumenjargal Sharav; Wolfram Sterry; Peter Walden
Journal:  PLoS One       Date:  2009-12-18       Impact factor: 3.240

3.  Using proteomics to identify preprocedural risk factors for contrast induced nephropathy.

Authors:  Michael R Bennett; Neelima Ravipati; Gary Ross; Mai T Nguyen; Russel Hirsch; Robert H Beekman; Leon Rovner; Prasad Devarajan
Journal:  Proteomics Clin Appl       Date:  2008       Impact factor: 3.494

Review 4.  An approach to the identification of T cell epitopes in the genomic era: application to Francisella tularensis.

Authors:  Michael Valentino; John Frelinger
Journal:  Immunol Res       Date:  2009-02-11       Impact factor: 2.829

5.  Serum anti-BPAG1 auto-antibody is a novel marker for human melanoma.

Authors:  Takashi Shimbo; Atsushi Tanemura; Takehiko Yamazaki; Katsuto Tamai; Ichiro Katayama; Yasufumi Kaneda
Journal:  PLoS One       Date:  2010-05-10       Impact factor: 3.240

6.  Immunoscreening of the extracellular proteome of colorectal cancer cells.

Authors:  Susanne Klein-Scory; Salwa Kübler; Hanna Diehl; Christina Eilert-Micus; Anke Reinacher-Schick; Kai Stühler; Bettina Warscheid; Helmut E Meyer; Wolff Schmiegel; Irmgard Schwarte-Waldhoff
Journal:  BMC Cancer       Date:  2010-02-25       Impact factor: 4.430

7.  Tumour auto-antibody screening: performance of protein microarrays using SEREX derived antigens.

Authors:  René Stempfer; Parvez Syed; Klemens Vierlinger; Rudolf Pichler; Eckart Meese; Petra Leidinger; Nicole Ludwig; Albert Kriegner; Christa Nöhammer; Andreas Weinhäusel
Journal:  BMC Cancer       Date:  2010-11-16       Impact factor: 4.430

8.  Simple screening method for autoantigen proteins using the N-terminal biotinylated protein library produced by wheat cell-free synthesis.

Authors:  Kazuhiro Matsuoka; Hiroaki Komori; Masato Nose; Yaeta Endo; Tatsuya Sawasaki
Journal:  J Proteome Res       Date:  2010-08-06       Impact factor: 4.466

9.  Proteome serological determination of tumor-associated antigens in melanoma.

Authors:  Michael Forgber; Uwe Trefzer; Wolfram Sterry; Peter Walden
Journal:  PLoS One       Date:  2009-04-17       Impact factor: 3.240

10.  A systems immunology approach to the host-tumor interaction: large-scale patterns of natural autoantibodies distinguish healthy and tumor-bearing mice.

Authors:  Yifat Merbl; Royi Itzchak; Tal Vider-Shalit; Yoram Louzoun; Francisco J Quintana; Ezra Vadai; Lea Eisenbach; Irun R Cohen
Journal:  PLoS One       Date:  2009-06-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.